



Gachon international
symposium for
Atherosclerosis,
Hypertension
AND
Stem cell

GO AHEAD Symposium

10th Anniversary of Gil Heart Center

May 14, Saturday, 2005

Gachon Hall, Gil Medical Center

Program Director

Eak Kyun Shin, MD, PhD

Kwang Kon Koh, MD, PhD, FACC, FAHA



Welcome!

Mark

May 14, Sat!

, 4 16 , 2005 ,


Endothelial Function Test as a Marker of Cardiovascular Disease

Seung Hwan Han, MD

Cardiology
Gachon Medical School
Incheon, Korea



Atherosclerosis: A progressive process



PHASE I: Initiation

PHASE II: Progression

PHASE III: Complication


Disease progression

Regulatory Properties of Endothelium

- Vascular tone: Nitric oxide
- Inflammation
- Hemostasis
- Extracellular matrix
- Local cell growth
- Solute transport

Koh KK. Cardiovasc Res 2000;47:648 (Review)

Koh KK. Cardiovasc Res 2002;55:714 (Review)



Endothelial Function Tests

1. Functional Change:

Endothelial vasomotor function test

2. Anatomical Change: **Carotid IMT, plaque**

3. Mediators: Biomarkers

(IL, **hs-CRP**, TNF- α , CAMs, MCP-1, MDA, MMP-9, **CD40L, adiponectin**, ..)

Endothelial Vasomotor Function Test

1. Coronary Endothelial Assessment

2. Peripheral Endothelial Assessment

- Non-invasive: Flow-Mediated Dilation

- Invasive: Plethysmography

Nitric Oxide

- Regulates vasomotor tone
- Inhibits inflammatory cell attachment
- Inhibits platelet aggregation and attachment
- Inhibits release of procoagulant factors
- Inhibits release of growth factors

Koh KK. Cardiovasc Res 2000;47:648 (Review)

Koh KK. Cardiovasc Res 2002;55:714 (Review)

Flow-Mediated Dilation (FMD)

Baseline 1



3273 77 (377)

16827763 Heart Center

004-10-12

9:21:11

DynRg 50dB

Persist Med

Fr Rate High

2D Opt:Res

16827763

L12-5 38 PVasc/PPK

12 Oct 04

9:21:10 am

Gil Heart Center

HD 3000

Srs:1



Img:2

HDI

<LS>

BASE 1

BASE 1



5:05:29

Z: 148%

50 (104m)

BW: 1



Reactive Hyperemia



3273 57 (377)

Heart Center

004-10-12

9:28:16

DynRg 50dB

Persist Med

Fr Rate High

2D Opt:Res

16827763

L12-5 38 PVasc/PPK

12 Oct 04

9:28:15 am

Gil Heart Center

HD 3000


Srs:1

Img:6

<LS>

H Y P
9 / 26 / 55

H Y P 9/26/55



5:07:08

Z: 148%


5: (104m)

BW: 1



Baseline 1

Reactive Hyperemia




Sensitivity and Specificity of FMD Tests in Predicting CAD

Test	Sensitivity (95% CI)	Specificity (95% CI)
Angina Pectoris (n = 112)	96/101; 95.1% (88.8-98.4)	5/21; 23.8% (8.2-47.2)
Exercise ECG testing (n = 112)	75/91; 82.4% (73.0-89.6)	12/21; 57.1% (34.0-78.2)
Myocardial Perfusion Imaging (n = 34)	30/30; 100.0% (88.4-100.0)	0/4; 0.0% (0-60.2)
FMD% (n = 122)	72/101; 71.3% (61.4-79.6)	17/21; 81% (58.1-94.6)

Prognostic Value of Endothelial Vasomotor Function

Study	Population	Vascular Bed	Test of Endothelial Function	No. of Patients	Follow-Up, mo	Clinical Events
Al Suwaidi et al ³⁶	CAD	Coronary resistance vessels	Acetylcholine	157	28	MI, cardiovascular death, revascularization, CHF
Schächinger et al ³⁷	CAD	Epicardial coronary arteries	Acetylcholine and flow-mediated dilation	147	92	MI, cardiovascular death, revascularization, unstable angina, ischemic stroke
Halcox et al ³⁸	CAD	Epicardial coronary arteries and resistance vessels	Acetylcholine	308	46	MI, cardiovascular death, unstable angina, stroke
Perticone et al ³⁹	Hypertension	Forearm resistance vessels	Acetylcholine	225	32	Cardiac, cerebrovascular, peripheral vascular
Heitzer et al ⁴⁰	CAD	Forearm resistance vessels	Acetylcholine	281	54	MI, cardiovascular deaths, ischemic stroke, revascularization
Neunteufl et al ⁴¹	CAD	Brachial arteries	Flow-mediated dilation	73	60	MI, revascularization
Gokce et al ⁴²	PAD	Brachial arteries	Flow-mediated dilation	187	1	Cardiovascular death, MI, unstable angina, stroke
Modena et al ⁴²	Hypertension, postmenopausal	Brachial arteries	Flow-mediated dilation	400	67	Cardiovascular events
Gokce et al ⁴³	PAD	Brachial arteries	Flow-mediated dilation	199	14	Cardiovascular death, MI, unstable angina, stroke
Targonski et al ⁴⁴	Risk factors, but normal coronary arteries	Coronary resistance vessels	Acetylcholine	503	16	Cerebrovascular events

Endothelial Vasomotor Function Test had a Long-Term Prognostic Value for CV Events




number exposed	3. tertile	40	32	27	27	23	16	7
to risk:	2. tertile	40	34	31	29	25	17	9
	1. tertile	39	32	28	26	20	15	4

Schachinger et al. Circulation 2000;101:1899


(10 yrs Follow-up)

Carotid Intima-Media Thickness (IMT)


B-Mode Ultrasound Examination of the Carotid Artery



Example of B-Mode Ultrasound Imaging





Increased IMT is an Independent Predictor of Future Cardiovascular Events



High-resolution ultrasound measurements of the intima and media of the common and internal carotid artery made in **5858 subjects ≥65 years of age**. New MI or stroke served as outcome variables in subjects without clinical CVD (n=4476) over a median follow-up of **6.2 years**.
O'Leary DH et al. *N Engl J Med.* 1999;340:14-22.


Plaque Size had the Greatest Prognostic Value Among all Ultrasound Parameters



1686 patients, CV events: Stroke, MI.

Spence JD, et al. *Stroke* 2002;33:2916


High-sensitivity CRP (hs-CRP)



Koh KK. Cardiovasc Res. 2002;55:714. (Review)

CRP Level and Cardiovascular Risk

CRP level
(mg/L)




Repeat test in one month
Exclude other process

High Risk


Intermediate Risk

Low Risk

Prospective Studies Relating Baseline CRP Levels to the Risk of First CV Events





CRP is a Stronger Predictor of Risk Than LDL Cholesterol Among Apparently Healthy Women




Women's Health Study
27939 women,
The median values:
CRP 1.52mg/L,
LDL cholesterol 123.7mg/dl

Ridker PM, et al. N Engl J Med 2002;347:1557.

hsCRP Provides Prognostic Information at all Levels of Framingham Risk Score and LDL cholesterol





CRP, Metabolic Syndrome, and Prediction of CV Events in the Framingham Offspring Study




Both CRP and MetS are independent predictors of new CVD events over 7 years

Elevated CRP Levels and Impaired Endothelial Vasoreactivity in Patients with CAD




CRP as a Mediator of Atherosclerosis



CRP inhibits BM-derived endothelial progenitor cell survival and differentiation.


CD40L

CD40L on vascular endothelial, SMCs, and Mononuclear phagocytes, mediates a broad Gamut of proatherothrombotic functions




*Szmitko et al
Circulation
2003;108:1917*

Patients with unstable angina have Elevated Plasma Levels of sCD40L



sCD40L is an Important Prognostic Indicator in Acute Coronary Syndromes




**The Effects of Simvastatin, Losartan,
and Combined Therapy on sCD40L in
Hypercholesterolemic, Hypertensive Patients**

**Seung Hwan Han, Kwang Kon Koh,
Eak Kyun Shin, Michael J. Quon**


J Am Coll Cardiol (submitted)

Combined Therapy and Losartan Reduces Plasma Levels of sCD40L




Adiponectin


Adiponectin can directly stimulate NO production from endothelium via activation of AMP-activated protein kinase



Adiponectin has Anti-inflammatory and Anti-atherogenic effects




Adiponectin and Endothelial Function




Strain-gauge phethysmography

Ouchi N, et al. Hypertension 2003;42:231.

Negative Relationship between Adiponectin and CRP




$r=-0.29$, $P<0.01$



$r=-0.89$, $P<0.01$

High Plasma Adiponectin Concentrations are Associated with Lower Risk of MI in Men



*Health Professionals Follow-up Study
Pischon T, et al. JAMA 2004;291:1730.*

Additive Beneficial Effects of Losartan Combined with Simvastatin in Treatment of Hypercholesterolemic, Hypertensive Patients

Kwang Kon Koh, Seung Hwan Han

Eak Kyun Shin, .. Michael J. Quon*

Cardiology, Gachon Medical School,


Incheon, Korea

Diabetes Unit, NIH, USA*


Circulation 2004;110:3687.

Combined Therapy or Losartan Alone Significantly Increases Insulin Sensitivity

Adiponectin



QUICKI



*QUICKI=Quantitative Insulin-Sensitivity Check Index, a surrogate index of insulin sensitivity, $QUICKI = 1/[\log(\text{insulin})+\log(\text{glucose})]$

Koh KK, et al. Circulation 2004;110:3687.

Additive Beneficial Effects of Fenofibrate Combined with Atorvastatin In Treatment of Combined Hyperlipidemia


**Kwang Kon Koh, Seung Hwan Han
Eak Kyun Shin, Michael J. Quon***

Diabetes Unit, NIH, USA*

ACC 2005, Orlando, USA

JACC 2005 (May)

Combined Therapy or Fenofibrate Alone Significantly Increases Adiponectin Levels



Conclusions (I)

- The endothelial dysfunction plays an important role in the pathogenesis of atherosclerosis.
- Endothelial function tests such as endothelial vasomotor function test, carotid artery IMT, biomarkers (hs-CRP, CD40L, adiponectin, etc..) are **useful predictors of CV events.**

Conclusions (II)

- The endothelial function tests are **useful research tools** to evaluate mechanisms of atherosclerosis and the effects of cardiovascular drugs.
- Further investigations for the development of **more simple, reliable, cost-effective endothelial function tests** are warranted.



Free Registration. Join Us!
Enjoy your personal time with
Circulation Editorial Team!

The poster features a background image of a stethoscope resting on a surface. The text is overlaid on this image. At the top right, the text "HypErtension", "AnD", and "Stem cell" is written in a red, sans-serif font. Below this, the main title "GO AHEAD Symposium" is written in a large, white, sans-serif font. Underneath the title, "10th Anniversary of Gil Heart Center" is written in a smaller, white, sans-serif font. The date and location, "May 14, Saturday, 2005" and "Gachon Hall, Gil Medical Center", are written in a yellow, sans-serif font. The names of the program directors, "Eak Kyun Shin, MD, PhD" and "Kwang Kon Koh, MD, PhD, FACC, FAHA", are written in a white, sans-serif font. At the bottom of the poster, there are three circular logos: the first is the Gil Heart Center logo, the second is the logo of the Korean Society of Hypertension, and the third is the logo of the Korean Society of Stem Cell Research.